A practical reference on purity testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Clinical significance == Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and the autosomal dominant cutis laxa. Other associated defects in elastin include Marfan syndrome, emphysema caused by α1-antitrypsin deficiency, atherosclerosis, Buschke–Ollendorff syndrome, Menkes syndrome, pseudoxanthoma elasticum, and Williams syndrome.
== History == The lines were first discovered in 1861 by Austrian anatomist Karl Langer (1819–1887), though he cited the surgeon Baron Dupuytren as being the first to recognise the phenomenon. Langer punctured numerous holes at short distances from each other into the skin of a cadaver with a tool that had a circular-shaped tip, similar to an ice pick. He noticed that the resultant punctures in the skin had ellipsoidal shapes. From this testing he observed patterns and was able to determine "line directions" by the longer axes of the ellipsoidal holes and lines.
An oncosphere is the larval form of a tapeworm once it has been ingested by an intermediate host animal. The intermediate host must ingest the tapeworm's eggs either in food or water – once this has happened, the eggs hatch and develop into oncospheres which will then burrow through the gut wall of the intermediate host in order to access the organs or tissues of that host where they will continue the next stage of their development as cysticerci or bladderworms. The bladderworm is a cyst created by the oncosphere. In order to become an adult tapeworm, a cysticercus must then be consumed by its definitive host (in either raw or undercooked meat) and establish itself by anchoring in that host's digestive tract. From there, the worm will grow in length and eventually produce proglottids which will exit the intestinal tract with other waste material and then burst, releasing the worm's eggs and completing the cycle.
=== Namibia === The Namibian Government reduced fuel levies by 50% for at least three months, using its National Energy Fund to stabilise prices until the end of June. Gas and oil exploration continues in the country, which expects to start producing oil by 2030.
Sources: en.wikipedia.org
=== Climate change === Panera Bread includes a "Cool Food" pledge in its campaign to "curb global warming". Panera Bread provides American consumers with dietary guidelines to help them change their eating patterns to help reduce carbon emissions. Through the Cool Foods pledge, the company uses traffic lights for different healthy and unhealthy foods. Foods labeled "green" are branded healthy, while those labeled "yellow" are warned to be consumed in moderation. In 2015, Panera Bread also announced its policy against the use of genetically modified organisms (GMOs), making it the first food chain in the country to question the safety and environmental friendliness of these foods.
These resynthesis experiments provided strong evidence: lichens are a product of symbiosis. The dual hypothesis gained influential supporters; in 1878, Royal Society president Joseph Hooker publicly endorsed Schwendener's theory in his annual address, and by 1880 leading British and American textbooks presented lichens as dual organisms. By 1900 the consensus had shifted. Most botanists now viewed lichens as fungi partnered with algae or cyanobacteria and reclassified them accordingly. Dissent lingered. In a 1909 poll of 42 botanists, Bruce Fink found 18 calling lichens dual organisms, 14 insisting they were fungi, and the rest undecided. Yet even holdouts were beginning to adopt the dual view. The Finnish lichenologist Edvard Vainio (1890) folded lichens into a fungal scheme—labelling them fungi that happen to form symbioses—a move said to have cost him a professorship. The next puzzle was how to classify lichens now that their dual nature was clear. Taxonomists questioned whether to base classification on fungal traits, algal traits, or both. In practice, they chose the fungus. Since the fungus governs reproduction and form, its fruiting bodies and spores carried the most taxonomic weight. By the late 1800s, taxonomists grouped lichens by fungal traits—spore colour, septation, fruiting-body type—rather than thallus shape or algal partner. The shift broke with thallus-based schemes and aligned lichen study with modern fungal taxonomy.
== Early years == Nickson is the daughter of a British father and a Chinese mother. After her father's death in an automobile accident when she was six, Nickson and her mother had to live in a house with three other families. Her grandmother often watched Chinese operas on television, and that kindled Nickson's interest in performing. When she was 17, Nickson left Singapore to study at the University of Hawaiʻi. Her successful audition for a play while she was there led to a shift in interest from business administration to drama. After two years, she left the university to work as a model, study acting, and perform in community theater productions.
== History == Normal pentane was discovered in 1862 by Carl Schorlemmer, who, while analyzing pyrolysis products of the cannel coal mined in Wigan, identified, separated by fractional distillation and studied a series of liquid hydrocarbons inert to nitric and sulfuric acids. The lightest of them, which he called hydride of amyl, had an empirical formula of C5H12, density of 0.636 at 17 °C and boiled between 39 and 40 °C. In the next year he identified the same compound in the Pennsylvanian oil. By 1872 he switched his nomenclature to the modern one, leading to it being called Pentane. Beyond Schorlemmer's initial work, scientists discovered that the molecular formula C5H12 could represent different structural arrangements, leading to the identification of isopentane and neopentane. This discovery contributed significantly to the understanding of isomerism and hydrocarbons in the 19th century. The high volatility and low boiling point of pentane made it useful as a solvent and in fuels. Its use expanded in the 1970s as a blowing agent for foams, replacing CFCs. The petroleum refining industry utilizes pentanes, particularly isopentane, to produce high-octane fuels.
==== Barnsley FC ==== Best FA Cup performance: Champions, 1911–12 (replay), Runners-up, 1909–10 Best EFL Cup performance: Quarter-finals, 1981–82 (replay) Best EFL Trophy performance: Champions, 2015–16 Best Anglo-Italian Cup performance: Group stage, 1992–93, 1993–94
Sources: en.wikipedia.org
== History == In May 2020, artesunate was approved for medical use in United States. Prior to this approval, intravenous (IV) artesunate was only available through the Expanded Access program of the U.S. Food and Drug Administration (FDA), which allowed the Centers for Disease Control and Prevention (CDC) to provide IV artesunate to people in the U.S. with severe malaria and to people with uncomplicated malaria who are unable to take oral medications under an investigational new drug (IND) protocol. There has been no FDA-approved drug for treatment of severe malaria in the United States since the marketing of quinidine was discontinued by the manufacturer in March 2019. The safety and efficacy of IV artesunate for the treatment of severe malaria was primarily evaluated in a randomized controlled trial in Asia (Trial 1) and a supportive published randomized controlled trial in Africa (Trial 2). Trial 1 was conducted at 10 sites in Myanmar, Bangladesh, India, and Indonesia. Trial 1 enrolled 1,461 participants who received either IV artesunate or the comparator drug quinine and included 202 pediatric participants younger than 15 years. Trial 2 included 5,425 randomized pediatric participants younger than 15 years of age with severe malaria who were treated with artesunate or quinine. In both trials, the number of participants treated with artesunate who died in the hospital was significantly lower than the number who died in the control group treated with quinine. Trial 2 was conducted during 2005–2010 in nine African countries.
Later, the Vice Minister of Mining said that "If [the mining companies] have all the mechanisms to present an extension, they can do so, the door is not closed." This contradicted Vasquez's initial announcement that there would be no extensions, "whether for exploitation, exploration or even shutdown." On 24 November 2021, PM Vásquez stated that there will be no "violation of legal certainty or unilateral closures," but that "the State assumes the function of supervising the processes of mine closure and environmental control in accordance with the legal frameworks." Additionally, the Council of Ministers released a statement assuring that the government sought active and positive relations with both mining companies and local populations. The statement also rejected violence in all forms but recognized the right to protest as a legitimate right. On 3 December 2021, the Las Bambas copper mine announced that it would shut down copper production starting mid-December due to continuous road blockades by protestors. The Ministry of Energy and Mines (Minem) said that the shutdown would have significant impact on GDP, and urged for the actors to maintain dialogue and reach a "satisfactory" agreement. Meanwhile, the National Society of Mining, Petroleum and Energy (SNMPE) criticized Minem, saying that "instead of dealing with a solution to the problem, it shows a concern that frankly generates a lot of confusion."
== History == After the clinical symptoms of envenomations by A. engaddensis were first described in the 1970's, the cardiotoxic effects of its venom were published in 1984. In 1988, a few months after the discovery and structures of endothelins were first reported, sequences of the first sarafotoxins, SRTX-a, SRTX-b, and SRTX-c, were published. Similarity to the structures of endothelins sparked experiments in comparing both groups and proving related activity in tested subjects, results that were published just a year later. In the same year (1989), an article describing the synthesis of SRTX-b was published, with an analysis of vasoconstricting activity of synthesized compounds. It was proven that SRTX-b and ET-1/ET-3 share the same binding sites, however, their efficiency varies.
==== Metabolism of proteins and lipids ==== Elevated levels of cortisol, if prolonged, can lead to proteolysis (breakdown of proteins) and muscle wasting. The reason for proteolysis is to provide the relevant tissue with a feedstock for gluconeogenesis; see glucogenic amino acids. The effects of cortisol on lipid metabolism are more complicated since lipogenesis is observed in patients with chronic, raised circulating glucocorticoid (i.e. cortisol) levels, although an acute increase in circulating cortisol promotes lipolysis. The usual explanation to account for this apparent discrepancy is that the raised blood glucose concentration (through the action of cortisol) will stimulate insulin release. Insulin stimulates lipogenesis, so this is an indirect consequence of the raised cortisol concentration in the blood but it will only occur over a longer time scale.
==== Temgicoluril ==== Temgicoluril (Mebicar) is an anxiolytic produced in Latvia and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the hypothalamus, as well as on all four basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.